Subtopic Deep Dive
Risk Assessment in Soft Tissue Fibrous Tumors
Research Guide
What is Risk Assessment in Soft Tissue Fibrous Tumors?
Risk assessment in soft tissue fibrous tumors involves prognostic models that integrate demographics, histopathology, genetics, and tumor features to predict metastasis and recurrence risks in solitary fibrous tumors (SFTs) and related neoplasms.
Key models include the 2012 Demicco risk assessment for SFTs based on 110 cases (556 citations) and its 2017 validation and refinement (411 citations). These incorporate age, size, mitoses, and necrosis for stratifying metastatic potential. Over 20 studies since 2012 have refined these for extrameningeal and meningeal SFTs.
Why It Matters
Risk models enable personalized treatment by identifying high-risk SFT patients for adjuvant therapy, reducing overtreatment in low-risk cases (Demicco et al., 2012; Demicco et al., 2017). In clinical practice, refined stratification guides surveillance intensity, with validation cohorts showing improved metastasis prediction accuracy (Demicco et al., 2017). For rare tumors like SFTs (1/million incidence), these tools support surgical decisions and radiotherapy use (Haas et al., 2020; Martín-Broto et al., 2021).
Key Research Challenges
Heterogeneous risk factors
Models must balance variables like age, size, mitoses, and necrosis across diverse SFT sites, but validation shows inconsistencies in extrameningeal cases (Demicco et al., 2017). Genetic markers like TERT mutations add complexity without universal prognostic value (Bahrami et al., 2016).
Limited validation cohorts
Rare tumor incidence limits large-scale prospective validation, with most models relying on retrospective data from 110-400 cases (Demicco et al., 2012). Meningeal SFT/HPC subtypes require separate grading due to NAB2-STAT6 fusion variability (Fritchie et al., 2018).
Molecular integration gaps
Incorporating NAB2-STAT6 fusions and TERT promoter mutations into histopathology-based scores remains inconsistent, hindering unified models (Huang and Huang, 2019). Stromal signatures from fibromatosis may inform but lack SFT-specific validation (Beck et al., 2008).
Essential Papers
Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model
Elizabeth G. Demicco, Min S Park, Dejka M. Araujo et al. · 2012 · Modern Pathology · 556 citations
Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model
Elizabeth G. Demicco, Michael J. Wagner, Robert G. Maki et al. · 2017 · Modern Pathology · 411 citations
Solitary fibrous tumor
Brian Davanzo, Robert E. Emerson, Megan Lisy et al. · 2018 · Translational Gastroenterology and Hepatology · 183 citations
Solitary fibrous tumor (SFT) is a rare tumor of mesenchymal origin that account for less than 2% of all soft tissue masses. Initially identified in the pleura, SFT has been identified in multiple a...
A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons
Javier Martín‐Broto, José L. Mondaza-Hernández, David S. Moura et al. · 2021 · Cancers · 147 citations
Solitary fibrous tumor (SFT) is a rare mesenchymal, ubiquitous tumor, with an incidence of 1 new case/million people/year. In the 2020 WHO classification, risk stratification models were recommende...
The fibromatosis signature defines a robust stromal response in breast carcinoma
Andrew H. Beck, Íñigo Espinosa, C. Blake Gilks et al. · 2008 · Laboratory Investigation · 113 citations
TERT promoter mutations and prognosis in solitary fibrous tumor
Armita Bahrami, Seungjae Lee, Inga‐Marie Schaefer et al. · 2016 · Modern Pathology · 110 citations
Expression of insulin-like growth factor 2 in mesenchymal neoplasms
Sonja E. Steigen, David F. Schaeffer, Robert B. West et al. · 2009 · Modern Pathology · 86 citations
Reading Guide
Foundational Papers
Start with Demicco et al. (2012, 556 citations) for the original 110-case SFT model defining age/size/mitoses/necrosis scores; then Beck et al. (2008) for stromal signatures applicable to fibrous tumors.
Recent Advances
Demicco et al. (2017, 411 citations) for model validation; Martín-Broto et al. (2021, 147 citations) for WHO risk stratification updates; Haas et al. (2020) for surgery-radiotherapy outcomes.
Core Methods
Clinicopathological scoring (age, size, mitoses, necrosis); genetic testing (TERT promoter, NAB2-STAT6 fusions); survival analysis via Cox regression and Kaplan-Meier on retrospective cohorts.
How PapersFlow Helps You Research Risk Assessment in Soft Tissue Fibrous Tumors
Discover & Search
Research Agent uses searchPapers('solitary fibrous tumor risk model') to retrieve Demicco et al. (2012, 556 citations), then citationGraph reveals 411 citing papers including Demicco et al. (2017) validation, while findSimilarPapers expands to TERT mutation studies like Bahrami et al. (2016). exaSearch handles rare fibrous tumor queries for global cohort data.
Analyze & Verify
Analysis Agent applies readPaperContent on Demicco et al. (2017) to extract risk score formulas, then runPythonAnalysis recreates Kaplan-Meier survival curves from reported hazard ratios using pandas and matplotlib. verifyResponse with CoVe cross-checks model predictions against raw cohort data, and GRADE grading scores evidence as high for validated models.
Synthesize & Write
Synthesis Agent detects gaps in molecular integration from Demicco (2012) vs. Bahrami (2016), flagging TERT contradictions; Writing Agent uses latexEditText for risk model tables, latexSyncCitations for 20+ SFT papers, and latexCompile to generate a prognostic review manuscript with exportMermaid for model flowcharts.
Use Cases
"Reproduce Demicco 2017 SFT risk model survival curves from paper data"
Research Agent → searchPapers → readPaperContent (Demicco 2017) → Analysis Agent → runPythonAnalysis (pandas survival analysis, matplotlib plots) → researcher gets validated Kaplan-Meier curves and p-values.
"Draft LaTeX review comparing SFT risk models with citations"
Research Agent → citationGraph (Demicco papers) → Synthesis Agent → gap detection → Writing Agent → latexEditText (intro), latexSyncCitations (20 papers), latexCompile → researcher gets compiled PDF with tables.
"Find code for NAB2-STAT6 fusion analysis in SFT genomics"
Research Agent → paperExtractUrls (Fritchie 2018) → paperFindGithubRepo → githubRepoInspect → Code Discovery workflow → researcher gets R scripts for fusion subtype grading.
Automated Workflows
Deep Research workflow scans 50+ SFT papers via searchPapers, structures risk model comparisons in a report with GRADE scores, and flags validation gaps. DeepScan's 7-step chain verifies Demicco model refinements (2012→2017) with CoVe checkpoints on cohort sizes. Theorizer generates hypotheses linking TERT mutations to stromal signatures (Bahrami 2016 + Beck 2008).
Frequently Asked Questions
What is the definition of risk assessment in soft tissue fibrous tumors?
It uses prognostic models integrating patient age, tumor size, mitoses, necrosis, and genetics like TERT mutations to predict SFT metastasis risk (Demicco et al., 2012).
What are the main methods in SFT risk models?
Demicco models score age >55 years, size >15cm, mitoses >4/10 HPF, and necrosis >10% for four-tier risk stratification, validated on 300+ cases (Demicco et al., 2017).
What are key papers on SFT risk assessment?
Demicco et al. (2012, 556 citations) proposed the initial model from 110 cases; Demicco et al. (2017, 411 citations) refined it; Martín-Broto et al. (2021) reviews WHO integration.
What are open problems in fibrous tumor risk assessment?
Standardizing molecular factors like NAB2-STAT6 subtypes and TERT across sites, plus prospective validation for radiotherapy impact (Fritchie et al., 2018; Haas et al., 2020).
Research Soft tissue tumor case studies with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Risk Assessment in Soft Tissue Fibrous Tumors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Soft tissue tumor case studies Research Guide